Immunodeficiency common variable – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Tue, 02 Jun 2026 04:16:28 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Immunodeficiency common variable – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 A Study of Leniolisib Safety and Effectiveness for Immune System Problems in Patients with Common Variable Immunodeficiency https://clinicaltrials.eu/trial/a-study-of-leniolisib-safety-and-effectiveness-for-immune-system-problems-in-patients-with-common-variable-immunodeficiency/ Wed, 29 Apr 2026 15:08:42 +0000 https://clinicaltrials.eu/trial/a-study-of-leniolisib-safety-and-effectiveness-for-immune-system-problems-in-patients-with-common-variable-immunodeficiency/ This study involves people with common variable immunodeficiency, which is a condition where the body’s immune system does not work properly and cannot produce enough antibodies to fight infections. People with this condition may also develop problems where the immune system becomes overactive in certain ways, leading to enlarged organs like the spleen, swollen lymph nodes, low blood cell counts, lung problems, or digestive system issues. The treatment being tested is leniolisib, which comes as a film coated tablet that is taken by mouth. Different doses of this medicine will be used in the study to find the right amount for each person.

The purpose of this study is to check if leniolisib is safe and well tolerated in people with this immune condition, and to see if it might help with the various problems caused by the overactive immune system. During the study, participants will receive leniolisib tablets for a period that can last up to several months. The study will monitor how the medicine affects the size of the spleen and lymph nodes, blood cell counts, lung function, and other signs of immune system problems. Regular check-ups will include physical examinations, blood tests to measure different types of immune cells and substances in the blood, imaging scans to look at organs and lymph nodes, and tests to check lung function if needed.

Throughout the study, doctors will carefully watch for any side effects or unwanted reactions to the medicine by checking vital signs like blood pressure and heart rate, doing laboratory tests, and asking about any symptoms or health changes. The study will also measure specific markers in the blood that show how active the immune system is, and will track changes in different types of white blood cells over time. Some participants may have additional tests depending on their specific symptoms, such as breathing tests for those with lung involvement or endoscopy procedures for those with digestive system problems.

]]> Trial of Ataluren for Severe Common Variable Immunodeficiency with Autoimmunity in Patients with LRBA Deficiency https://clinicaltrials.eu/trial/trial-of-ataluren-for-severe-common-variable-immunodeficiency-with-autoimmunity-in-patients-with-lrba-deficiency/ Wed, 29 Apr 2026 14:58:18 +0000 https://clinicaltrials.eu/trial/trial-of-ataluren-for-severe-common-variable-immunodeficiency-with-autoimmunity-in-patients-with-lrba-deficiency/ This clinical trial is focused on studying a rare genetic disorder called LRBA deficiency. This condition affects the immune system and is caused by specific genetic mutations. People with this disorder often have too many immune cells, known as lymphocytes, which can lead to various symptoms such as chronic diarrhea, low levels of antibodies, and frequent infections. The disease can also increase the risk of developing lymphoma, a type of cancer. The trial will use a treatment called Ataluren, also known by its code name PTC-124, which is taken as an oral suspension.

The purpose of the study is to evaluate how effective Ataluren is in reducing the symptoms associated with LRBA deficiency, such as lymphocyte overgrowth and chronic diarrhea, and to assess how well the patient tolerates the treatment. The study will involve a single patient with this condition, and the treatment will be administered over a period of time to observe any improvements in symptoms and overall quality of life.

Throughout the study, the patient’s health will be monitored to see if there are improvements in their quality of life, weight, and frequency of diarrhea episodes, as well as a reduction in hospital visits. Additionally, the study will look at specific markers in the blood to see if there are changes in the expression of certain proteins related to the immune system. The trial aims to provide valuable insights into the potential benefits of Ataluren for individuals with LRBA deficiency.

]]> Study on the Effect of Human Normal Immunoglobulin on Lung Disease in Patients with Primary Antibody Deficiency https://clinicaltrials.eu/trial/study-on-the-effect-of-human-normal-immunoglobulin-on-lung-disease-in-patients-with-primary-antibody-deficiency/ Wed, 29 Apr 2026 14:27:23 +0000 https://clinicaltrials.eu/trial/study-on-the-effect-of-human-normal-immunoglobulin-on-lung-disease-in-patients-with-primary-antibody-deficiency/ This clinical trial is focused on studying the progression of lung disease in individuals with Primary Antibody Deficiency (PAD). PAD is a condition where the body has difficulty producing enough antibodies to fight infections. The study includes various types of PAD, such as Common Variable Immunodeficiency (CVID), IgA deficiency, and Agammaglobulinemia. The treatment being tested involves the use of Human Normal Immunoglobulin, a substance derived from blood that helps boost the immune system. Several medications containing this substance are being used in the study, including Nanogam, HyQvia, Privigen, KIOVIG, Gammanorm, CUTAQUIG, GAMMAGARD S/D, Hizentra, Octagam, and Cuvitru.

The purpose of the study is to determine if higher doses of immunoglobulin can better protect against the progression of lung disease in people with PAD. Participants will receive either a standard dose or a higher dose of immunoglobulin. The study will monitor the health of participants over time, focusing on lung health and the number of respiratory infections they experience. The study will also look at the overall health costs and quality of life for participants.

Throughout the study, participants will have regular check-ups and may undergo tests such as CT scans to assess lung health. They will also keep a diary to track any respiratory symptoms and report any missed days from work or school due to illness. The study aims to provide valuable information on the effectiveness and cost-efficiency of different dosing strategies for managing PAD and its impact on lung health.

]]>